牛皮癣治疗市场按治疗层级、给药途径、分销管道、最终用户、疾病严重程度和患者年龄组划分 - 全球预测 2025-2032

预计到 2032 年，牛皮癣治疗市场将成长至 510.7 亿美元，复合年增长率为 10.06%。

主要市场统计数据
基准年2024年	237.1亿美元
预计2025年	260.8亿美元
预测年份：2032年	510.7亿美元
复合年增长率（%）	10.06%

简洁的基本概述，解释临床进展、不断发展的护理途径和商业性需求如何重塑牛皮癣治疗策略

引言部分透过描述临床复杂性、不断发展的治疗方法以及不断变化的医疗服务模式，为深入探索银屑病治疗奠定了基础。近年来，治疗方法创新已从传统的外用药物和照光治疗扩展到生技药品和标靶小分子疗法，这种多样化改变了临床医生、相关人员和患者群体的期望。随着关于新作用机制和长期安全性的证据不断积累，临床决策管道变得更加精细，要求临床团队将生物标记洞察、合併症管理和患者偏好整合到个人化治疗方案中。

同时，商业格局正在透过更复杂的分销安排、基本契约实验以及旨在解决依从性和疗效问题的数位化患者援助计画来适应这些临床转变。付款人和医疗系统越来越需要强有力的真实世界证据和健康经济学原理来支持可及性，而製造商则正在投资于长期疗效追踪和整合护理模式。在此背景下，引言强调了跨研究、监管、报销和供应链职能部门的多学科合作的必要性，以便将科学进步转化为患者照护的可衡量改进和可持续的商业性成果。

临床创新、监管变革和以患者为中心的护理模式如何推动银屑病治疗开发和商业化的根本转变

科学突破、监管调整和患者期望的转变正在推动银屑病治疗领域的变革——这些因素正在改写临床研发和药物开发的规则。免疫学的进步推动了高选择性生技药品和精准靶向小分子药物的开发，重新定义了疗效指标和耐受性预期，并迫使临床医生重新思考给药顺序、联合用药策略和剂量优化。监管机构正在透过调整途径来应对，以支持加速证据生成、有条件核准和上市后数据共享，从而在保持安全监测的同时加快患者用药。

除了产品层面的创新之外，医疗服务交付和商业模式也正在转向融合诊所管理、送货上门选项和数位化依从性支援的一体化病人历程。随着支付方将支出与可衡量的临床效益挂钩，基本契约试点和基于结果的报销安排正变得越来越普遍。同时，生物相似药的进入和竞争性定价压力迫使製造商透过提供服务、患者援助计划和证据生成来实现差异化。这些综合转变迫使相关人员重新评估其临床通讯协定、合作策略和投资重点，以在快速发展的生态系统中保持竞争力。

评估 2025 年关税政策的变化如何改变银屑病治疗供应链的弹性、筹资策略和临床物流

2025年宣布的美国关税的累积影响，为银屑病治疗价值链上的企业带来了成本压力和战略考量，影响了供应链的韧性、筹资策略和製造地的决策。关税导致原料、活性药物成分和某些生技药品倡议的成本上涨，促使製造商重新评估其供应商的多样性，并加快近岸生产计划以降低风险。同时，经销商和专业药房正在经历采购经济状况的变化，这要求他们重新协商条款并调整库存策略，以在控製成本的同时保持服务水准。

这些动态也影响临床项目物流和临床实验药物供应计划，临床实验药物采购和跨境运输将面临更严格的审查，并可能出现延误。为此，申办方正在透过多资讯来源采购、策略储备以及将增强的海关风险模型整合到采购和财务工作流程中来优化物流。随着相关人员与政策制定者的互动，倡导豁免和分阶段实施是更广泛的风险缓解策略的一部分。这些措施有助于维持医疗和临床实验室运作的连续性，同时在新的关税环境下重新调整成本结构和策略重点。

详细的细分洞察揭示了治疗层级、给药途径、分销管道和患者特征如何决定临床和商业性方法

关键细分洞察揭示了治疗层级、给药途径、分销管道、最终用户、疾病严重程度和患者年龄如何影响银屑病领域的治疗选择、商业策略和服务设计。治疗层级的区分——生技药品、照光治疗、小分子药物和外用药物——指南临床定位和付款人对话。生技药品进一步分为 IL-12/23、IL-17、IL-23 和 TNF 抑制剂，每种抑制剂都表现出不同的功效和安全性，影响治疗顺序考量。照光治疗，如准分子雷射、窄带 UVB 和 PUVA，是根据患者族群和临床情况选择的。小分子药物，如 JAK 抑制剂和 PDE4 抑制剂，提供影响依从性和监测需求的口服替代品。外用药物，如Calcineurin抑制剂、皮质类固醇和维生素 D 类似物，是轻度病例和维持策略的核心。

注射、口服和外用药物的给药途径影响患者的偏好和依从性，而注射剂型（如自动注射器、预填充式注射器和管瓶）则影响自我给药的可行性和临床工作流程。口服剂型（如胶囊和锭剂）在便利性和监测方面各不相同。医院药局、零售药局和专业药局（包括送货上门和诊所内配药的专业子通路）之间的分销管道细微差别影响着病患的取得和支援计画的设计。诊所、皮肤病中心以及二级和三级医院的最终用户环境决定了管理能力和交付管道。将疾病严重程度分层为轻度、中度和重度决定了治疗强度和护理协调，成人和儿童人群中的患者年龄组决定了不同的安全性、剂量和依从性方法。这些细分结合起来，为产品开发重点、商业化策略和服务产品提供了讯息，使临床效益与现实世界患者的需求一致。

全球主要地区的不同法规结构、付款人结构和采用模式将如何改变准入策略和营运重点

美洲、欧洲、中东和非洲以及亚太地区的动态呈现出不同的法规环境、付款人结构和应用模式，这些都影响着银屑病治疗的战略重点。在美洲，卫生技术评估框架和与私人付款人的谈判动态决定了打入市场策略，推动了对真实世界证据和患者支持基础设施的投资，以解决处方集配置和报销障碍。同时，欧洲、中东和非洲的管理体制和付款人系统各不相同，区域中心和国家报销政策创造了差异化的采用管道，并需要製定个人化的证据基础和定价策略。

在亚太地区，生技药品在某些市场的快速普及、生技药品产能的不断提升，以及对价格承受能力和本地法规合规性的关注，促使製造商考虑分阶段上市，并与区域经销商和契约製造製造商合作。跨区域合作和在地化循证驱动的措施日益支持全球产品生命週期，而供应链决策（例如区域製造地和分销管道）则体现了在成本、上市速度和法规合规性之间取得平衡的需求。这些区域差异需要细緻的上市方案和灵活应变的商业模式，既要尊重当地临床实践和报销现实，又要充分利用全球临床证据和营运规模。

了解主要企业如何平衡产品线创新、策略合作伙伴关係和以患者为中心的商业化以保持竞争优势

公司层面在干癣治疗领域的行动体现了产品线创新、合作伙伴关係以及差异化患者服务模式的融合，这些因素共同塑造了竞争优势。主要企业正在优先发展有针对性的生技药品和小分子项目，并投资于针对特定机制的长期安全性研究，以支持差异化产品说明书和临床医生的信心。策略合作，包括与许可、共同开发、合约研究和生产合作伙伴的合作，正在加快临床开发速度，并扩大复杂生技药品的生产能力。

主要企业正在透过实施全面的病人参与平台来减少治疗启动和持续性的障碍，这些平台将护理师主导的支持、数位化依从性工具和简化的报销协助相结合。一些公司正在与付款人试行基本契约结果的合同，以使定价与实际绩效指标保持一致，而其他公司则专注于产品组合合理化和生命週期管理，以扩大治疗的相关性。在竞争和政策压力下，寻求保护净利率并维持可及性的公司也纷纷投资于製造敏捷性、供应链多元化和生物相似药能力。总体而言，公司策略体现了科学差异化与服务导向商业化的务实结合，旨在满足未满足的临床需求和付款人需求。

为领导者提供实用且可操作的建议，以协调临床差异化、分销灵活性和付款人参与度，从而加强市场地位和患者治疗效果

为了掌握干癣治疗的长期价值，产业领导者应优先考虑一种整合的方法，将临床开发、商业模式和供应链韧性协调一致。首先，投资差异化机制并累积强有力的核准后证据，将有助于临床推广和支付方参与，从而在报销谈判中占据更有利的地位。其次，公司应设计灵活的分销和给药途径，例如家庭给药方案和方便临床使用的注射剂，以满足不断变化的患者偏好，并减少治疗启动的障碍。

第四，开发一个融合依从性工具、远端监控和护理支援的数位化病患支援生态系统，将改善现实世界的疗效和病患留存率。第五，透过基于价值的试点计画和透明的疗效报告，积极与付款方合作，可以加速处方集的纳入和风险分担安排。最后，领导阶层应强调跨职能协作，包括协调医学事务、HEOR、上市和竞争团队，将临床洞察转化为令人信服的价值提案，并确保营运准备就绪，以保持竞争优势。

一种透明、多层次的调查方法，结合文献综合、专家访谈和三角测量，以产生可靠的、可供决策的发现

调查方法整合了一手和二手研究证据流，对定性专家见解进行三角检验，并应用结构化检验，以确保分析的严谨性和与决策者的相关性。此方法首先全面回顾同侪审查文献、监管指南、临床试验註册和公开的技术摘要，以建立基础依证。此外，也对临床专家、供应链经理和市场准入专家进行了半结构化访谈，以补充二手研究，从而捕捉实际营运观点和新兴趋势，而这些趋势在已出版的资讯来源中并不常见。

我们运用资料三角测量技术，将这些定性输入与监管备案文件和产品标籤资讯整合，以验证关于作用机制、剂量特征和临床定位的关键声明。在整个过程中，我们采用了品管，包括与多位独立专家最后覆核、审查利益衝突，并不断完善细分框架，以确保清晰度和适用性。我们的调查方法强调透明度、可重复性和相关人员相关性，使其成为临床、商业和监管领域策略决策和产业计画的实践基础。

结论性综合强调了整合科学、服务设计和策略敏捷性的必要性，以将治疗创新转化为持久的临床和商业性成功

总而言之，银屑病治疗领域的特点是科学进步日新月异、交付模式不断变化以及商业性和监管环境日益复杂，这需要整个生态系统的相关人员制定适应性策略。选择性生技药品和标靶小分子药物的进展正在提高临床预期，而分销创新和付款人计划则要求更完善的证据生成和患者支持机制。供应链和政策变化（包括与关税相关的中断）凸显了製造敏捷性和采购多元化对于维持护理和临床营运连续性的重要性。

未来的成功取决于各机构能否将临床差异化与切实可行的商业化和供应链解决方案相结合，透过透明的疗效报告吸引付款方参与，并设计以患者为中心的服务，从而提高依从性和长期疗效。在相关人员应对地区差异和竞争压力的过程中，跨职能协作和积极主动的政策参与仍然至关重要。最终，科学、服务和策略的周密协调将决定哪些机构能够创新，从而切实改善银屑病患者的疗效。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 长期安全性和有效性的改善增加了 IL-23 抑制剂的采用率
• 银屑病生物相似药的推广提高了可负担性和市场竞争力
• 整合微生物组标靶治疗探索肠道-皮肤轴在干癣治疗中的调节作用
• 人们对局部JAK 抑制剂的兴趣日益浓厚，这种抑制剂可提供局部治疗，同时减少全身暴露
• 根据基因组和生物标记见解制定个人化牛皮癣治疗方法
• 使用远距皮肤病学平台可改善患者获得专门的牛皮癣治疗和监测的机会

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 牛皮癣治疗市场（依治疗层级）

• 生技药品
  • IL-12/23抑制剂
  • IL-17抑制剂
  • IL-23抑制剂
  • TNF抑制剂
• 照光治疗
  • 准分子雷射
  • 窄频 UVB
  • 普瓦
• 小分子
  • JAK抑制剂
  • PDE4抑制剂
• 外用药物
  • Calcineurin抑制剂
  • 皮质类固醇
  • 维生素D类似物

9. 牛皮癣治疗市场（依给药途径）

• 注射
  • 自动注射器
  • 预填充式注射器
  • 管瓶
• 口服
  • 胶囊
  • 药片
• 局部的
  • 奶油
  • 凝胶
  • 软膏

第 10 章 银屑病治疗市场（依分销管道）

• 医院药房
• 零售药局
• 专业药房
  • 宅配
  • 院内配药

第 11 章 牛皮癣治疗市场（以最终用户划分）

• 诊所
• 皮肤科中心
• 医院
  • 次要的
  • 第三

第 12 章 牛皮癣治疗市场（依疾病严重程度）

• 温和的
• 缓和
• 严重

第十三章 银屑病治疗市场（依患者年龄层）

• 成人
• 孩子们

第十四章 牛皮癣治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 银屑病治疗市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 银屑病治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Incyte Corporation
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Limited

The Psoriasis Therapeutics Market is projected to grow by USD 51.07 billion at a CAGR of 10.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 23.71 billion
Estimated Year [2025]	USD 26.08 billion
Forecast Year [2032]	USD 51.07 billion
CAGR (%)	10.06%

A concise foundational overview explaining how clinical advances, evolving care pathways, and commercial imperatives are reshaping psoriasis therapeutic strategies

The introduction sets the scene for an in-depth exploration of psoriasis therapeutics by framing the clinical complexity, evolving treatment modalities, and shifting care delivery models that define the current landscape. Over recent years, therapeutic innovation has expanded beyond traditional topicals and phototherapy to include a multiplicity of biologic and targeted small molecule approaches, and this diversification has altered stakeholder expectations across clinicians, payers, and patient communities. As evidence accumulates for new mechanisms of action and longer-term safety profiles, clinical decision pathways have become more nuanced, demanding that clinical teams integrate biomarker insights, comorbidity management, and patient preference into individualized regimens.

Concurrently, the commercial environment is adapting to these clinical shifts through more sophisticated distribution arrangements, value-based contracting experiments, and digital patient support programs that address adherence and outcomes. Payers and health systems increasingly require robust real-world evidence and health economic arguments to support access, leading manufacturers to invest in longitudinal outcome tracking and integrated care models. In this context, the introduction underscores the need for multidisciplinary collaboration across research, regulatory, reimbursement, and supply chain functions to translate scientific advances into measurable improvements in patient care and sustainable commercial outcomes.

How clinical innovation, regulatory evolution, and patient-centered care models are jointly driving a fundamental transformation of psoriasis therapy development and commercialization

Transformative shifts within the psoriasis therapeutic landscape are driven by converging scientific breakthroughs, regulatory recalibrations, and changing patient expectations that together rewrite the rules of clinical development and market engagement. Advances in immunology have led to highly selective biologics and precision-targeted small molecules that redefine efficacy benchmarks and tolerability expectations, prompting clinicians to reconsider sequencing, combination strategies, and dose optimization. Regulatory agencies have responded with pathway adjustments that accommodate accelerated evidence generation, conditional approvals, and collaborative post-marketing data commitments, which in turn accelerate patient access while maintaining safety oversight.

Beyond product-level innovation, care delivery and commercial models are shifting toward integrated patient journeys that blend clinic-based administration, home delivery options, and digital adherence supports. Value-based contracting pilots and outcomes-based reimbursement arrangements are becoming more prevalent as payers align spending with measurable clinical benefits. Meanwhile, biosimilar entry and competitive price dynamics are prompting manufacturers to differentiate through service offerings, patient support programs, and evidence generation. These combined shifts compel stakeholders to re-evaluate clinical protocols, partnership strategies, and investment priorities to remain competitive in a rapidly evolving ecosystem.

Assessing how tariff policy shifts in 2025 have reshaped supply chain resilience, sourcing strategies, and clinical logistics across psoriasis therapeutics

The cumulative impact of United States tariffs announced in 2025 has introduced discrete cost pressures and strategic considerations for organizations operating across the psoriasis therapeutic value chain, affecting supply chain resilience, sourcing strategies, and manufacturing footprint decisions. Tariff-induced increases in the cost of raw materials, active pharmaceutical ingredients, and certain biologics components have prompted manufacturers to re-assess supplier diversity and to accelerate near-shore manufacturing initiatives to mitigate exposure. In parallel, distributors and specialty pharmacies have experienced shifts in procurement economics that require renegotiation of commercial terms and reconfiguration of inventory strategies to preserve service levels while containing costs.

These dynamics have also influenced clinical program logistics and trial supply planning, as investigational material sourcing and cross-border shipments have become subject to additional scrutiny and potential delays. In response, sponsors are optimizing logistics through multi-sourced procurement, strategic stockpiling, and enhanced tariff-risk modeling embedded in procurement and finance workflows. Regulatory and policy dialogue remains a crucial variable; as stakeholders engage with policymakers, advocacy for exemptions or phased approaches has become part of broader risk mitigation strategies. Together, these measures have helped organizations preserve continuity of care and clinical trial operations while recalibrating cost structures and strategic priorities under the new tariff environment.

Detailed segmentation insights revealing how therapeutic class, administration route, distribution pathways, and patient characteristics determine clinical and commercial approaches

Key segmentation insights reveal how therapeutic class, route of administration, distribution channel, end user, disease severity, and patient age shape treatment selection, commercial strategy, and service design across the psoriasis space. Therapeutic class differentiation between biologics, phototherapy, small molecules, and topicals guides clinical positioning and payer conversations, with biologics further divided across IL-12/23, IL-17, IL-23, and TNF inhibitors each exhibiting distinct efficacy and safety attributes that influence sequencing considerations. Phototherapy modalities such as excimer laser, narrowband UVB, and PUVA serve defined patient cohorts and clinical contexts, while small molecule options like JAK inhibitors and PDE4 inhibitors offer oral alternatives that affect adherence and monitoring needs. Topical agents, including calcineurin inhibitors, corticosteroids, and vitamin D analogues, remain central for milder disease and for maintenance strategies.

Route of administration considerations among injectable, oral, and topical options influence patient preference and adherence, with injectable delivery subtypes such as auto-injectors, pre-filled syringes, and vials affecting self-administration feasibility and clinic workflows. Oral formulations across capsule and tablet forms alter convenience and monitoring profiles. Distribution channel nuances across hospital pharmacy, retail pharmacy, and specialty pharmacy, including specialty subchannels of home delivery and in-clinic dispensing, shape patient access and support program design. End user context across clinics, dermatology centers, and hospitals-spanning secondary and tertiary facilities-determines administration capabilities and referral pathways. Disease severity stratification into mild, moderate, and severe directs therapeutic intensity and care coordination, while patient age groups of adult and pediatric populations require differentiated safety, dosing, and adherence approaches. Collectively, these segmentation lenses inform product development priorities, commercialization tactics, and service offerings that align clinical benefit with real-world patient needs.

How distinct regulatory frameworks, payer structures, and adoption patterns across key global regions reshape access strategies and operational priorities

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific present distinct regulatory environments, payer architectures, and adoption patterns that influence strategic priorities for psoriasis therapeutics. In the Americas, health technology assessment frameworks and private payer negotiation dynamics shape market access strategies, driving investment in real-world evidence and patient support infrastructure to address formulary placement and reimbursement hurdles. Meanwhile, Europe, Middle East & Africa comprises diverse regulatory regimes and heterogeneous payer systems where regional centers of excellence and national reimbursement policies create differentiated uptake paths and require tailored evidence dossiers and pricing strategies.

Asia-Pacific features rapid adoption in selected markets, growing biologics manufacturing capacity, and a strong emphasis on affordability and local regulatory alignment, prompting manufacturers to consider tiered launch approaches and partnerships with regional distributors and contract manufacturers. Cross-region collaborations and localized evidence generation efforts increasingly support global product lifecycles, and supply chain decisions such as regional manufacturing hubs and distribution pathways reflect the need to balance cost, speed-to-market, and regulatory compliance. These regional distinctions require nuanced market entry playbooks and adaptive commercial models that respect local clinical practices and reimbursement realities while leveraging global clinical evidence and operational scale.

Insights into how leading companies balance pipeline innovation, strategic alliances, and patient-centric commercialization to sustain competitive advantage

Company-level behavior in psoriasis therapeutics reflects a blend of pipeline innovation, collaborative partnerships, and differentiated patient service models that together shape competitive positioning. Leading organizations have prioritized targeted biologic and small molecule programs, investing in mechanistic precision and long-term safety studies to support differentiated label claims and clinician confidence. Strategic collaborations, including licensing, co-development, and alliances with contract research and manufacturing partners, have accelerated time-to-clinic and expanded capacity for complex biologic production.

Commercially, companies are increasingly deploying holistic patient engagement platforms that combine nurse-led support, digital adherence tools, and streamlined reimbursement assistance to reduce barriers to initiation and persistence. Several firms have embraced outcomes-based contracting pilots with payers to align pricing with real-world performance metrics, while others focus on portfolio rationalization and lifecycle management to extend therapeutic relevance. Manufacturing agility, supply chain diversification, and investments in biosimilar readiness represent additional themes as companies seek to protect margins and maintain access in the face of competitive and policy pressures. Overall, corporate strategies exhibit a pragmatic mix of scientific differentiation and service-oriented commercialization to address both clinical unmet needs and payer demands.

Practical, actionable recommendations for leaders to align clinical differentiation, distribution flexibility, and payer engagement to strengthen market position and patient outcomes

Industry leaders should prioritize an integrated approach that aligns clinical development, commercial models, and supply chain resilience to capture long-term value in psoriasis therapeutics. First, investing in mechanistic differentiation and robust post-approval evidence generation will support both clinical uptake and payer engagement, enabling stronger positioning during reimbursement negotiations. Second, companies should design flexible distribution and administration pathways that include home-based delivery options and clinic-friendly injectables to meet evolving patient preferences and reduce barriers to treatment initiation.

Third, fostering partnerships with regional manufacturers and logistics providers can mitigate tariff and geopolitical risk while improving supply continuity, and fourth, developing digital patient support ecosystems that combine adherence tools, remote monitoring, and nursing support will enhance real-world outcomes and retention. Fifth, engaging proactively with payers through value-based pilots and transparent outcomes reporting can accelerate formulary inclusion and shared-risk arrangements. Finally, leadership should emphasize cross-functional alignment-linking medical affairs, HEOR, market access, and commercial teams-to translate clinical insights into compelling value propositions and operational readiness that sustain competitive performance.

A transparent, multi-layered research methodology combining literature synthesis, expert interviews, and triangulation to produce robust, decision-ready insights

The research methodology synthesizes primary and secondary evidence streams, triangulates qualitative expert insights, and applies structured validation to ensure analytical rigor and relevance for decision-makers. The approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, and publicly available technical briefings to establish a foundational evidence base. This secondary research was complemented by semi-structured interviews with clinical specialists, supply chain managers, and market access professionals to capture practical operational perspectives and emergent trends that are not always visible in published sources.

Data triangulation techniques integrated these qualitative inputs with regulatory filings and product labeling information to validate key claims around mechanisms of action, administration characteristics, and clinical positioning. Throughout the process, quality controls included cross-checks with multiple independent experts, scrutiny for conflicts of interest, and iterative refinement of segmentation frameworks to ensure clarity and applicability. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, enabling the research to serve as a pragmatic foundation for strategic decision-making and operational planning across clinical, commercial, and regulatory domains.

A conclusive synthesis highlighting the necessity of integrated science, service design, and strategic agility to convert therapeutic innovation into enduring clinical and commercial success

In conclusion, the psoriasis therapeutics landscape is characterized by rapid scientific progress, changing delivery models, and an increasingly complex commercial and regulatory environment that together require adaptive strategies from stakeholders across the ecosystem. Advances in selective biologics and targeted small molecules have raised clinical expectations, while distribution innovations and payer experimentation demand more sophisticated evidence generation and patient support mechanisms. Supply chain and policy shifts, including tariff-related disruptions, have underscored the importance of manufacturing agility and procurement diversification to sustain continuity of care and clinical operations.

Looking ahead, success will hinge on the ability of organizations to integrate clinical differentiation with pragmatic commercialization and supply chain solutions, to engage payers through transparent outcomes reporting, and to design patient-centered services that improve adherence and long-term outcomes. Cross-functional collaboration and proactive policy engagement will remain essential as stakeholders navigate regional variability and competitive pressures. Ultimately, thoughtful alignment of science, service, and strategy will determine which organizations translate innovation into meaningful improvements for patients living with psoriasis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of IL-23 inhibitors driven by improved long-term safety and efficacy profiles
• 5.2. Expansion of biosimilars for psoriasis leading to increased affordability and market competition
• 5.3. Integration of microbiome-targeted therapies exploring gut-skin axis modulation in psoriasis management
• 5.4. Growing interest in topical JAK inhibitors offering localized treatment with reduced systemic exposure
• 5.5. Development of personalized psoriatic treatment regimens based on genomic and biomarker-driven insights
• 5.6. Use of teledermatology platforms enhancing patient access to specialized psoriasis care and monitoring

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Therapeutics Market, by Therapeutic Class

• 8.1. Biologics
  • 8.1.1. IL-12/23 Inhibitors
  • 8.1.2. IL-17 Inhibitors
  • 8.1.3. IL-23 Inhibitors
  • 8.1.4. TNF Inhibitors
• 8.2. Phototherapy
  • 8.2.1. Excimer Laser
  • 8.2.2. Narrowband Uvb
  • 8.2.3. Puva
• 8.3. Small Molecules
  • 8.3.1. JAK Inhibitors
  • 8.3.2. PDE4 Inhibitors
• 8.4. Topicals
  • 8.4.1. Calcineurin Inhibitors
  • 8.4.2. Corticosteroids
  • 8.4.3. Vitamin D Analogues

9. Psoriasis Therapeutics Market, by Route Of Administration

• 9.1. Injectable
  • 9.1.1. Auto-Injector
  • 9.1.2. Pre-Filled Syringe
  • 9.1.3. Vial
• 9.2. Oral
  • 9.2.1. Capsule
  • 9.2.2. Tablet
• 9.3. Topical
  • 9.3.1. Cream
  • 9.3.2. Gel
  • 9.3.3. Ointment

10. Psoriasis Therapeutics Market, by Distribution Channel

• 10.1. Hospital Pharmacy
• 10.2. Retail Pharmacy
• 10.3. Specialty Pharmacy
  • 10.3.1. Home Delivery
  • 10.3.2. In-Clinic Dispensing

11. Psoriasis Therapeutics Market, by End User

• 11.1. Clinics
• 11.2. Dermatology Centers
• 11.3. Hospitals
  • 11.3.1. Secondary
  • 11.3.2. Tertiary

12. Psoriasis Therapeutics Market, by Disease Severity

• 12.1. Mild
• 12.2. Moderate
• 12.3. Severe

13. Psoriasis Therapeutics Market, by Patient Age Group

• 13.1. Adult
• 13.2. Pediatric

14. Psoriasis Therapeutics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Psoriasis Therapeutics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Psoriasis Therapeutics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. Novartis AG
  • 17.3.3. Johnson & Johnson
  • 17.3.4. Eli Lilly and Company
  • 17.3.5. Pfizer Inc.
  • 17.3.6. Amgen Inc.
  • 17.3.7. Bristol-Myers Squibb Company
  • 17.3.8. Incyte Corporation
  • 17.3.9. Merck & Co., Inc.
  • 17.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 289. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 290. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 291. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 292. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 293. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 294. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 295. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 296. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 297. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 298. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 299. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
• TABLE 300. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
• TABLE 301. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 302. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 303. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 304. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 305. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 306. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 307. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 308. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 309. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 310. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 311. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
• TABLE 312. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2032 (USD MILLION)
• TABLE 313. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 314. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 315. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 316. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 317. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
• TABLE 318. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
• TABLE 319. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE